Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer
AUSTIN, Texas, Aug. 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the recent formation of a subsidiary, Volition Veterinary Diagnostics Development LLC ("Volition Veterinary"), and the appointment of animal health expertNathan Dewsbury as its Chief ...
VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Aug. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onTuesday, August 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2019 in addition to providing a business upd...
Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock
AUSTIN, Texas, July 24, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a further strengthening of its balance sheet with an existing investor exercising the balance of its warrant to purchase$4.8 million in aggregate amount of shares of our common stock...
VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China
AUSTIN, Texas, July 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") to help introduce the Nu.Q(TM) platf...
VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding
AUSTIN, Texas, July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately$1.4 million from the Walloon Region, Belgium. To date, Agen...
VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update
AUSTIN, Texas, May 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter endedMarch 31, 2019. Volition management will host a conference call tomorrow,May 9, at 8:30 a.m. U.S. Eastern Time to dis...
VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer
AUSTIN, Texas, May 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale ...
VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, May 6, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onThursday, May 9 at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2019 in addition to providing a business update. ...
VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report
ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") hosted a Capital Markets Day at the New York Stock Exchange today to update interested parties on its recent progress. Volition has also issued a Company Update Report; a downloadable version of w...
VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics
ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned subsidiary, Belgian Volition SPRL, withTexas A&M University, a member of The Texas A&M University System. Pur...
VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China
ISNES, Belgium, March 28, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") with an expectation of negotiating and entering into a ...
VolitionRx Limited to Present at Conferences in March & April 2019
ISNES, Belgium, March 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations,Scott Powell, is scheduled to present at three conferences in March andApril 2019. During the conferences, Dr. Powell will ou...
VolitionRx Limited to Present at Conferences in the U.S. Next Week
ISNES, Belgium, March 15, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer, Mr.Cameron Reynolds, is scheduled to present at two conferences in the U.S. next week. During the conferences, Mr. Reynolds will outline Volition...
VolitionRx Limited Announces Full Fiscal Year 2018 Financial Results and Business Update
ISNES, Belgium, March 13, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year endedDecember 31, 2018. Volition management will host a conference call tomorrow,March 14, at 8:30a.m. U.S. Eastern...
VolitionRx Limited Schedules Full Year 2018 Earnings Conference Call and Business Update
ISNES, Belgium, March 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onThursday, March 14 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2018, in conjunction with the f...
VolitionRx Limited to Expand its Nu.Q(TM) Trials to Veterinary Diagnostics
ISNES, Belgium, Oct. 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced very encouraging preliminary results from a proof of concept study using its Nu.Q™ diagnostic test in veterinary medicine at the 10th anniversary meeting of the Belgian Technology Mi...
VolitionRx Limited Releases Video Featuring Interviews with its Scientific Advisory Board
ISNES, Belgium, Sept. 26 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today released a video featuring members of its Scientific Advisory Board (SAB). The video was taken at Volition's laboratories inBelgium during the last SAB meeting and features members of the SAB...
VolitionRx Limited to Attend Multiple Conferences in September
ISNES, Belgium, Sept. 5, 2018 /PRNewswire/ -- VolitionRx Limited
VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update
ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter endedJune 30, 2018. Volition management will host a conference call to discuss these results and provide a further business u...
Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer
ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer. Vo...
